Article Text

PDF

FRI0175 Clinical manifestations of antiphospholipid syndrome in females with obstetric pathology and antiphospholipid antibodies
  1. LA Krysova,
  2. OM Lesnyak,
  3. NV Putylova,
  4. Remizova II,
  5. LN Yurchenko
  1. Obstetric Pathology, Ural Institute of Mother and Child Care, Yekaterinburg, Russia

Abstract

Objectives Antiphospholipid antibodies (APA) were studied in 94 women with a history of reccurent fetal loss and other obstetric complications associated with antiphospholipid syndrome (APS) such as fetal growth retardation, pre-eclampsia, intrauterine fetal death.

Results APA were found in 43,6% of them: lupus anticoagulant (LA) in 24,5%; anticardiolipin antibodies (aCL) ? in 10,6% and 8,5% had LA and aCL mixture. Only 4,5% of studied women had moderate or high levels of IgG aCL.

All women were examined in order to find extragenital manifestations of APS. Clinical features associated with APS including reccurent miscarriages were found in 81,6% women with APA circulation. Extragenital features of APS had 45,5% patients: reccurent arterial or venous thrombosis, thrombocytopenia in 20,4% cases. 25,1% women had possible APS features such as livedo reticularis, damage of cardiac valves, stroke, transient ischaemic attacks, migraine, leg ulcers, syndrome Reino. 29,5% APA-positive women had arterial hypertension. The most serious vascular complications took place in group with high and moderate levels of IgG aCL. One case of systemic lupus erythematosus was diagnosed (according to the American Rheumatism Association criteria).

Conclusion Women with APA circulation had not only obstetical complications of APS. In 45,5% of them definite and possible features of this pathology were found.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.